NDAINTRAVENOUSSOLUTION
Approved
Feb 2023
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed 33m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PREVDUO is a fixed-dose intravenous combination of neostigmine methylsulfate (an acetylcholinesterase inhibitor) and glycopyrrolate (an anticholinergic agent) approved in February 2023. It is indicated for the reversal of neuromuscular blockade induced by neuromuscular blocking agents during anesthesia. The combination mechanism allows neostigmine to reverse neuromuscular blockade while glycopyrrolate mitigates cholinergic side effects.
Peak12.0 years to LOE
Early-stage peak product with limited competitive pressure provides opportunity for rapid market penetration and team expansion in hospital-based commercial roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PREVDUO represents an early-stage peak asset with minimal linked jobs in current market, suggesting either an emerging role base or undervalued opportunity. Working on this product offers exposure to hospital-based specialty pharma, perioperative medicine, and a growing franchise with extended IP protection.
Hospital Sales RepresentativeAccount Executive (Anesthesia/OR)
Worked on PREVDUO at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.